Managing weight loss and quality of life in pancreatic cancer patients
Managing metabolic disruption in pancreatic cancer to prevent weight loss and improve quality of life
This study is looking at how certain diabetes medications can help people with pancreatic cancer manage their blood sugar and maintain a healthy weight, making life a little easier for those dealing with weight loss and diabetes.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10892257 on NIH RePORTER |
What this research studies
This research focuses on improving the quality of life for patients with pancreatic cancer by addressing metabolic disruptions that lead to weight loss and cachexia. It investigates the effectiveness of various anti-diabetic medications in managing hyperglycemia, which is common in these patients. By comparing the outcomes of different treatments, the research aims to identify the best options for maintaining healthy weight and managing blood sugar levels. This approach is particularly important as many pancreatic cancer patients experience both diabetes and weight loss, complicating their treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are experiencing weight loss and hyperglycemia.
Not a fit: Patients with pancreatic cancer who do not experience weight loss or hyperglycemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of weight loss and better overall quality of life for pancreatic cancer patients.
How similar studies have performed: While there is limited comparative effectiveness research specifically in pancreatic cancer, similar approaches in other cancer types have shown promise in improving patient outcomes.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Flory, James H — Sloan-Kettering Inst Can Research
- Study coordinator: Flory, James H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.